检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:魏萍[1,2] 陈文弦[1,2] 朱春生[1,2] 周润锁 穆继珍[1,2]
机构地区:[1]第四军医大学唐都医院耳鼻咽喉科 [2]武警贵州总队医院
出 处:《中华耳鼻咽喉科杂志》1998年第1期35-37,共3页Chinese Journal of Otorhinolaryngology
摘 要:目的用喉癌裸鼠模型研究抗人喉癌单克隆抗体的免疫导向作用,为诊断和治疗提供依据和方向。方法用高效碘标法标记三株混合抗人喉癌单克隆抗体(McAbLC)经腹腔注入人喉癌裸鼠模型体内,用单光子发射计算机断层(singlephotonemissioncomputedtomography,ECT)扫描显像并测定肿瘤、血液和组织单位质量浓集的放射性占注入总放射性的百分比(%ID/g)和肿瘤与主要器官组织的放射性比值(T/NT)。结果单克隆抗体在一定时限内能够选择性的浓集在移植瘤组织内,96h可获得满意的肿瘤显像,实验组肿瘤组织的%ID/g为18.8±0.61,对照组肿瘤组织的%ID/g为4.46±0.82,两组比较差异有显著性(P<0.01,t=34.97)。结论用放射性核素标记抗人喉癌单克隆抗体在活体内能选择性地与人喉癌细胞结合,用ECT扫描可以识别肿瘤所在的部位和大小,对肿瘤病灶及转移病灶的定位诊断有一定的实用价值。Objective To investigate the specific autoradiographic diagnosis of laryngeal carcinoma and its metastasis. Methods Three strains of the mixed monoclonal antibodies against human laryngeal carcinoma (McAbLC9,11,12) labelled with 131 I were injected(intraperitoneally) into the nude mice bearing squamous cell carcinoma.The tumor autoradiography was done by single photo emission computed tomography (ECT).The percent injected dose/g of tumor were measured, and the radioactivity ratio of tumor to non tumor tissues(T/NT) were calculated.Results The 131 I McAbLC 9, 11, 12 can accumulate in the area of the laryngeal carcinoma within limited time, and demonstrate a satisfactory tumor imaging at 96h. In experimental groups: The %ID/g of tumor tissues ( ±s,n =6)was 18. 8± 0. 61;The %ID/g of tumor tissues in the control group was 4.46±0. 82 ( ±s,n =6) at 96h. The difference was statistically significant ( P <0.01, t = 34. 97).Conclusion The results suggest that 131 I McAbLC9,11,12 is specific and sensitive in recognising human laryngeal carcinoma cell, and the area and size of tumor can be easily detected by ECT. It is feasible for localization of tumor and its metastasis.
分 类 号:R739.650.3[医药卫生—肿瘤]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.3